COGT

Cogent BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$12.75

-61.1% vs current

Most likely

Base case

50%

Probability

Target price

$8.50

-74.1% vs current

B-

Bear case

25%

Probability

Target price

$5.10

-84.4% vs current

AI sentiment snapshot

Latest data as of 2025-12-07

AI commentary

Market is event-driven and cautious: limited liquidity magnifies reactions to clinical or financing news. Investors are focused on upcoming readouts and runway; rumors of partnerships drive episodic volume. Overall sentiment is neutral-to-cautious—tilted toward the base case unless positive data or funding clarity arrives.

RankAlpha Sentiment AI - 2025-12-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventUpcoming clinical data readout (early-stage program)High impact

Potential readout from an early clinical study could move valuation; timing uncertain — monitor company press releases/SEC filings for exact date [#10Qp12], [#PR-2025-06-01].

-eventRegulatory update or partnership announcementHigh impact

Biotech partnership or regulatory communication could materially re-rate shares; typical for small-cap biotechs [#PR-2024-11-15].

-catalystNegative trial result / clinical setbackHigh impact

Failed efficacy/safety readout would likely trigger sharp sell-off in biotech peers and this stock [#10Qp12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-12-07 • Updated nightlySource: Internal modelMethodology